Sign in or create an account to add this stock to your watchlist.
About Aevi Genomic Medicine (NASDAQ:GNMX)
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNMX
CUSIPN/A
Phone610-254-4201
Debt
Debt-to-Equity RatioN/A
Current Ratio5.78
Quick Ratio5.78
Price-To-Earnings
Trailing P/E Ratio-1.99
Forward P/E Ratio-2.75
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.38 per share
Price / Book4.34
Profitability
EPS (Most Recent Fiscal Year)($0.83)
Net Income$-34,710,000.00
Net MarginsN/A
Return on Equity-160.09%
Return on Assets-127.64%
Miscellaneous
Employees17
Outstanding Shares59,340,000
Aevi Genomic Medicine (NASDAQ:GNMX) Frequently Asked Questions
What is Aevi Genomic Medicine's stock symbol?
Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX."
How were Aevi Genomic Medicine's earnings last quarter?
Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) announced its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.01. View Aevi Genomic Medicine's Earnings History.
What price target have analysts set for GNMX?
2 brokerages have issued 1-year price targets for Aevi Genomic Medicine's shares. Their forecasts range from $1.50 to $7.00. On average, they anticipate Aevi Genomic Medicine's stock price to reach $4.25 in the next twelve months. View Analyst Ratings for Aevi Genomic Medicine.
Who are some of Aevi Genomic Medicine's key competitors?
Some companies that are related to Aevi Genomic Medicine include Jounce Therapeutics (JNCE), Agenus (AGEN), NanoString Technologies (NSTG), NantKwest (NK), Allena Pharmaceuticals (ALNA), Cellular Biomedicine Group (CBMG), Osiris Therapeutics (OSIR), ADMA Biologics (ADMA), Arsanis (ASNS), Fennec Pharmaceuticals (FENC), Organovo (ONVO), Compugen (CGEN), Pluristem Therapeutics (PSTI), Eiger Biopharmaceuticals (EIGR) and Aptose Biosciences (APTO).
Who are Aevi Genomic Medicine's key executives?
Aevi Genomic Medicine's management team includes the folowing people:
- Mr. Michael F. Cola, Chief Exec. Officer, Pres and Director (Age 58)
- Mr. Brian D. Piper MBA, CFO & Corp. Sec. (Age 46)
- Dr. Garry A. Neil, Chief Scientific Officer (Age 64)
- Dr. Nir Shapir Ph.D., Sr. VP of R&D
- Dr. David A. Fitts M.P.H., Ph.D., Head of Statistical Sciences & Data Management and VP
Has Aevi Genomic Medicine been receiving favorable news coverage?
News articles about GNMX stock have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aevi Genomic Medicine earned a coverage optimism score of 0.13 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.77 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Aevi Genomic Medicine's major shareholders?
Aevi Genomic Medicine's stock is owned by many different of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (0.17%). Company insiders that own Aevi Genomic Medicine stock include Garry Arthur Neil, Michael F Cola, Philip R Harper and Sol J Barer. View Institutional Ownership Trends for Aevi Genomic Medicine.
Which major investors are buying Aevi Genomic Medicine stock?
GNMX stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have bought Aevi Genomic Medicine stock in the last two years include Garry Arthur Neil, Michael F Cola, Philip R Harper and Sol J Barer. View Insider Buying and Selling for Aevi Genomic Medicine.
How do I buy shares of Aevi Genomic Medicine?
Shares of GNMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aevi Genomic Medicine's stock price today?
One share of GNMX stock can currently be purchased for approximately $1.65.
How big of a company is Aevi Genomic Medicine?
Aevi Genomic Medicine has a market capitalization of $94.94 million. The biotechnology company earns $-34,710,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Aevi Genomic Medicine employs 17 workers across the globe.
How can I contact Aevi Genomic Medicine?
Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected]
MarketBeat Community Rating for Aevi Genomic Medicine (GNMX)
MarketBeat's community ratings are surveys of what our community members think about Aevi Genomic Medicine and other stocks. Vote "Outperform" if you believe GNMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aevi Genomic Medicine (NASDAQ:GNMX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Aevi Genomic Medicine in the last 12 months. Their average twelve-month price target is $4.25, suggesting that the stock has a possible upside of 157.58%. The high price target for GNMX is $7.00 and the low price target for GNMX is $1.50. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.67 | 2.67 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.25 | $4.25 | $4.25 | $7.50 |
| Price Target Upside: | 157.58% upside | 235.65% upside | 235.65% upside | 492.32% upside |
Aevi Genomic Medicine (NASDAQ:GNMX) Consensus Price Target History
Aevi Genomic Medicine (NASDAQ:GNMX) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Aevi Genomic Medicine (NASDAQ:GNMX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aevi Genomic Medicine (NASDAQ GNMX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.70%
Institutional Ownership Percentage: 22.83%
Aevi Genomic Medicine (NASDAQ GNMX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/17/2017 | Garry Arthur Neil | Insider | Buy | 75,000 | $1.26 | $94,500.00 | 114,774 |  |
| 10/17/2017 | Michael F Cola | CEO | Buy | 119,047 | $1.26 | $149,999.22 | 218,483 | |
| 10/17/2017 | Sol J Barer | Director | Buy | 421,032 | $1.26 | $530,500.32 | 1,028,032 | |
| 8/23/2017 | Philip R Harper | Major Shareholder | Buy | 10,361 | $1.20 | $12,433.20 | 4,870,344 | |
| 8/10/2017 | Philip R Harper | Major Shareholder | Buy | 20,470 | $1.19 | $24,359.30 | 4,865,683 | |
| 4/28/2017 | Sol J Barer | Director | Buy | 100,000 | $1.57 | $157,000.00 | 607,000 | |
| 4/26/2017 | Sol J Barer | Director | Buy | 100,000 | $1.54 | $154,000.00 | 507,000 | |
| 3/24/2017 | Philip R Harper | Major Shareholder | Buy | 1,058,531 | $1.78 | $1,884,185.18 | 4,786,682 | |
(Data available from 1/1/2013 forward)
Aevi Genomic Medicine (NASDAQ GNMX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Aevi Genomic Medicine (GNMX) versus ADMA Biologics (ADMA) Head-To-Head Analysis
www.americanbankingnews.com - May 25 at 11:14 PM |
| Curis (CRIS) and Aevi Genomic Medicine (GNMX) Head-To-Head Review
www.americanbankingnews.com - May 24 at 5:17 AM |
 | Wired News - uniQure Announced Presentation of Preclinical Data Demonstrating Advances in Distribution of Gene Therapy at ASGCT Annual Meeting in Chicago
finance.yahoo.com - May 22 at 8:23 AM |
 | Aevi Genomic Medicine: Try Subgroups Until It Works?
seekingalpha.com - May 20 at 5:50 PM |
| Aevi Genomic Medicine, Inc. (GNMX) Given $5.00 Consensus Price Target by Analysts
www.americanbankingnews.com - May 18 at 11:47 AM |
| Aevi Genomic Medicine, Inc. to Post Q2 2018 Earnings of ($0.15) Per Share, Jefferies Group Forecasts (GNMX)
www.americanbankingnews.com - May 18 at 7:30 AM |
| Aevi Genomic Medicine (GNMX) Issues Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 16 at 10:35 AM |
| Aevi Genomic Medicine: 1Q Earnings Snapshot
finance.yahoo.com - May 15 at 5:45 PM |
| Aevi Genomic Medicine Reports First Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 8:36 AM |
| Zacks: Analysts Expect Aevi Genomic Medicine, Inc. (GNMX) to Announce -$0.15 EPS
www.americanbankingnews.com - May 12 at 11:24 AM |
| What Are Analysts Expecting From Aevi Genomic Medicine Inc (NASDAQ:GNMX) Over The Next Few Years?
finance.yahoo.com - May 8 at 5:32 PM |
| Aevi Genomic Medicine (GNMX) Lifted to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 5:12 PM |
| Analysts Expect Aevi Genomic Medicine, Inc. (GNMX) to Post ($0.15) EPS
www.americanbankingnews.com - May 2 at 11:19 PM |
| Aevi Genomic Medicine (GNMX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 11:10 AM |
 | Form DEF 14A Sage Therapeutics, Inc. For: Jun 06
www.streetinsider.com - April 30 at 5:10 PM |
 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of ...
www.businesswire.com - April 30 at 5:10 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Aevi Genomic Medicine, Inc. -- GNMX
finance.yahoo.com - April 30 at 5:10 PM |
 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Aevi Genomic Medicine, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
www.prnewswire.com - April 29 at 8:54 PM |
| Zacks: Brokerages Expect Aevi Genomic Medicine, Inc. (GNMX) to Announce -$0.15 EPS
www.americanbankingnews.com - April 24 at 11:18 PM |
| Zacks: Analysts Set $5.00 Target Price for Medgenics Inc (GNMX)
www.americanbankingnews.com - April 17 at 1:32 AM |
| Head-To-Head Contrast: Medgenics (GNMX) & Momenta Pharmaceuticals (MNTA)
www.americanbankingnews.com - April 13 at 9:21 PM |
| Medgenics Inc (GNMX) Expected to Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - April 8 at 1:17 AM |
| Investor Expectations to Drive Momentum within Brooks Automation, Broadridge Financial Solutions, Vivint Solar, Northwest Natural Gas, Aevi Genomic Medicine, and Northern Oil and Gas — Discovering Underlying Factors of Influence
finance.yahoo.com - April 6 at 8:35 AM |
| Brokerages Anticipate Medgenics Inc (GNMX) to Announce ($0.15) Earnings Per Share
www.americanbankingnews.com - April 2 at 9:16 PM |
| Analysts Set $5.00 Target Price for Medgenics Inc (GNMX)
www.americanbankingnews.com - March 30 at 1:21 PM |
| Medgenics Inc (GNMX) Expected to Earn Q1 2018 Earnings of ($0.14) Per Share
www.americanbankingnews.com - March 26 at 1:04 AM |
| GNMX: Q4 2017 Results / Operational Update
finance.yahoo.com - March 22 at 5:31 PM |
| GNMX: ASCEND Timeline On-Track, Topline ~Mid-2018. Additional Pipeline Expansion
finance.yahoo.com - March 22 at 5:31 PM |
| Brokerages Anticipate Medgenics Inc (GNMX) to Post -$0.15 Earnings Per Share
www.americanbankingnews.com - March 22 at 1:18 AM |
| Aevi Genomic Medicine to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 20 at 8:36 AM |
| Brokerages Set $5.33 Price Target for Medgenics Inc (GNMX)
www.americanbankingnews.com - March 16 at 3:18 PM |
| FY2019 EPS Estimates for Medgenics Inc (GNMX) Cut by Analyst
www.americanbankingnews.com - March 16 at 2:20 PM |
| Medgenics Inc Expected to Earn Q1 2018 Earnings of ($0.15) Per Share (GNMX)
www.americanbankingnews.com - March 15 at 7:57 AM |
| Aevi Genomic Medicine, Inc. to Host Earnings Call
finance.yahoo.com - March 13 at 8:33 AM |
| Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 13 at 8:33 AM |
| Head-To-Head Survey: Anavex Life Sciences (AVXL) & Medgenics (GNMX)
www.americanbankingnews.com - March 12 at 11:27 AM |
| Aevi expands drug development deal with Japanese biopharm firm
finance.yahoo.com - March 7 at 6:28 PM |
| Aevi Genomic Medicine Expands Collaboration with Kyowa Hakko Kirin
finance.yahoo.com - March 7 at 8:25 AM |
| Aevi Genomic Medicine to Host Conference Call to Announce Fourth Quarter and Year End 2017 Financial Results
finance.yahoo.com - March 6 at 8:22 AM |
| -$0.15 EPS Expected for Medgenics Inc (GNMX) This Quarter
www.americanbankingnews.com - March 4 at 9:14 PM |
| Analysts Set $5.25 Price Target for Medgenics Inc (GNMX)
www.americanbankingnews.com - February 18 at 11:12 PM |
| Zacks: Brokerages Expect Medgenics Inc (GNMX) Will Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - February 16 at 5:18 AM |
| FY2018 EPS Estimates for Medgenics Inc (GNMX) Increased by Analyst
www.americanbankingnews.com - February 15 at 11:20 AM |
| FY2022 Earnings Forecast for Medgenics Inc Issued By Jefferies Group (GNMX)
www.americanbankingnews.com - February 14 at 4:12 PM |
| Comparing Medgenics (GNMX) & Trillium Therapeutics (TRIL)
www.americanbankingnews.com - February 1 at 12:01 PM |
| Analysts Set $5.17 Price Target for Medgenics Inc (GNMX)
www.americanbankingnews.com - January 31 at 7:14 PM |
| Zacks: Analysts Anticipate Medgenics Inc (GNMX) to Announce -$0.17 EPS
www.americanbankingnews.com - January 30 at 5:08 AM |
| Zacks: Medgenics Inc (GNMX) Given $5.17 Consensus Price Target by Analysts
www.americanbankingnews.com - January 23 at 11:10 PM |
| Contrasting Mateon Therapeutics (MATN) & Aevi Genomic Medicine (GNMX)
www.americanbankingnews.com - January 15 at 11:40 AM |
| Aevi Genomic Medicine, Inc. (GNMX) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - January 13 at 7:52 AM |
Aevi Genomic Medicine (NASDAQ:GNMX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aevi Genomic Medicine (NASDAQ:GNMX) Income Statement, Balance Sheet and Cash Flow Statement
Aevi Genomic Medicine (NASDAQ GNMX) Stock Chart for Sunday, May, 27, 2018
Loading chart…
